Evidence map›Paper›PMID 39139869›Full record

ArticleJournal of arrhythmia2024

Clinical differences between drug-induced type 1 Brugada pattern and syndrome.

Avi Sabbag, Gisella Amoroso, Orr Tomer, Giulio Conte, Roy Beinart, Eyal Nof, Tardu Özkartal, Pierre Ollitrault, Mikael Laredo, Oholi Tovia-Brodie and 4 more

Abstract read
In one paragraph

Article in Journal of arrhythmia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Avi SabbagLeviev Heart Institute The Chaim Sheba Medical Center Tel Hashomer Israel.ORCID https://orcid.org/0000-0003-4295-6679
Gisella AmorosoOspedale Civile SS Annunziata Savigliano Italy.ORCID https://orcid.org/0000-0001-5992-4265
Orr TomerLeviev Heart Institute The Chaim Sheba Medical Center Tel Hashomer Israel.ORCID https://orcid.org/0000-0002-3752-1411
Giulio ConteCardiocentro Ticino Institute Lugano Switzerland.
Roy BeinartLeviev Heart Institute The Chaim Sheba Medical Center Tel Hashomer Israel.
Eyal NofLeviev Heart Institute The Chaim Sheba Medical Center Tel Hashomer Israel.
Tardu ÖzkartalCardiocentro Ticino Institute Lugano Switzerland.
Pierre OllitraultElectrophysiology Unit, Cardiology Department, Caen University Hospital Unicaen Caen France.
Mikael LaredoSorbonne Université, AP-HP, Groupe Hospitalier Pitié-Salpêtrière Institut de Cardiologie Paris France.
Oholi Tovia-BrodieJesselson Integrated Heart Center Shaare Zedek Medical Center Jerusalem Israel.
Estelle GandjbakhchElectrophysiology Unit, Cardiology Department, Caen University Hospital Unicaen Caen France.
Michele de BenedictisOspedale Civile SS Annunziata Savigliano Italy.
Rachel M A Ter BekkeDepartment of Cardiology, Cardiovascular Research Institute Maastricht (CARIM) Maastricht University Medical Center Maastricht the Netherlands.
Anat MilmanLeviev Heart Institute The Chaim Sheba Medical Center Tel Hashomer Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Diagnosis of Brugada syndrome (BrS) may be established by exposing a Type 1 Brugada pattern using a sodium channel blocker. Data on the outcomes of different patient populations with drug-induced Type 1 Brugada pattern are limited. The present study reports on the characteristics and outcome of subjects with ajmaline induced Type 1 Brugada pattern. Methods: A multicenter retrospective study including all consecutive cases of ajmaline-induced Type 1 Brugada pattern from seven centers. Results: A total of 260 patients (69.9% males, mean age 43.4 ± 13.5) were included. Additional characteristics included history of syncope ( Conclusion: Less than half of subjects with ajmaline-induced Brugada pattern met current criteria for BrS. These individuals had very low rate of adverse outcomes during a follow up of 3 years, irrespective of the indication for the test or eligibility for the BrS diagnosis.

Indexed as

ajmalineBrugada ECG patternBrugada syndromesodium channel blocker challenge test

Identifiers

PMID39139869
PMCPMC11317691

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.